Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.

Hepatocellular carcinoma (HCC) management is rapidly evolving as systemic therapies and locoregional treatments are increasingly combined across disease ...

A University of Kentucky Markey Cancer Center study shows that a targeted form of radiation therapy can be safely delivered ...

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of ...

—Building on earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer, plus identify factors ...